Selected research
Industry Research
Hepatocellular Carcinoma Drug Industry Research Report 2026
Market perspective
The global Hepatocellular Carcinoma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hepatocellular Carcinoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hepatocellular Carcinoma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hepatocellular Carcinoma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hepatocellular Carcinoma Drug include Teva Pharmaceutical, Sun Pharmaceutical, Johnson & Johnson, Novartis, Sigma-Tau Group, Pacira, Luye Pharma, Kingond Pharm and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hepatocellular Carcinoma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hepatocellular Carcinoma Drug Market by Company
Teva Pharmaceutical
Sun Pharmaceutical
Johnson & Johnson
Novartis
Sigma-Tau Group
Pacira
Luye Pharma
Kingond Pharm
Gilead Sciences
Fudan-Zhangjiang
CSPC
Hepatocellular Carcinoma Drug Segment by Type
Ablation Therapy
Brachytherapy
Chemotherapy
Hepatocellular Carcinoma Drug Segment by Application
Surgical Resection
Ablation
Liver Transplantation
Hepatocellular Carcinoma Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatocellular Carcinoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hepatocellular Carcinoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatocellular Carcinoma Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hepatocellular Carcinoma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hepatocellular Carcinoma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hepatocellular Carcinoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ablation Therapy
- Brachytherapy
- Chemotherapy
Applications
- Surgical Resection
- Ablation
- Liver Transplantation
Companies covered
- Teva Pharmaceutical
- Sun Pharmaceutical
- Johnson & Johnson
- Novartis
- Sigma-Tau Group
- Pacira
- Luye Pharma
- Kingond Pharm
- Gilead Sciences
- Fudan-Zhangjiang
- CSPC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hepatocellular Carcinoma Drug Market Size (2021-2032)
- 2.2.2 Global Hepatocellular Carcinoma Drug Sales (2021-2032)
- 2.2.3 Global Hepatocellular Carcinoma Drug Market Average Price (2021-2032)
- 2.3 Hepatocellular Carcinoma Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ablation Therapy
- 2.3.3 Brachytherapy
- 2.3.4 Chemotherapy
- 2.4 Hepatocellular Carcinoma Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Surgical Resection
- 2.4.3 Ablation
- 2.4.4 Liver Transplantation
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hepatocellular Carcinoma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hepatocellular Carcinoma Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Hepatocellular Carcinoma Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Hepatocellular Carcinoma Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Hepatocellular Carcinoma Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hepatocellular Carcinoma Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hepatocellular Carcinoma Drug, Product Type & Application
- 3.8 Global Manufacturers of Hepatocellular Carcinoma Drug, Established Date
- 3.9 Global Hepatocellular Carcinoma Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Hepatocellular Carcinoma Drug Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Hepatocellular Carcinoma Drug Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Hepatocellular Carcinoma Drug Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Sigma-Tau Group
- 4.5.1 Sigma-Tau Group Company Information
- 4.5.2 Sigma-Tau Group Business Overview
- 4.5.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sigma-Tau Group Hepatocellular Carcinoma Drug Product Portfolio
- 4.5.5 Sigma-Tau Group Recent Developments
- 4.6 Pacira
- 4.6.1 Pacira Company Information
- 4.6.2 Pacira Business Overview
- 4.6.3 Pacira Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pacira Hepatocellular Carcinoma Drug Product Portfolio
- 4.6.5 Pacira Recent Developments
- 4.7 Luye Pharma
- 4.7.1 Luye Pharma Company Information
- 4.7.2 Luye Pharma Business Overview
- 4.7.3 Luye Pharma Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Luye Pharma Hepatocellular Carcinoma Drug Product Portfolio
- 4.7.5 Luye Pharma Recent Developments
- 4.8 Kingond Pharm
- 4.8.1 Kingond Pharm Company Information
- 4.8.2 Kingond Pharm Business Overview
- 4.8.3 Kingond Pharm Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kingond Pharm Hepatocellular Carcinoma Drug Product Portfolio
- 4.8.5 Kingond Pharm Recent Developments
- 4.9 Gilead Sciences
- 4.9.1 Gilead Sciences Company Information
- 4.9.2 Gilead Sciences Business Overview
- 4.9.3 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Gilead Sciences Hepatocellular Carcinoma Drug Product Portfolio
- 4.9.5 Gilead Sciences Recent Developments
- 4.10 Fudan-Zhangjiang
- 4.10.1 Fudan-Zhangjiang Company Information
- 4.10.2 Fudan-Zhangjiang Business Overview
- 4.10.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product Portfolio
- 4.10.5 Fudan-Zhangjiang Recent Developments
- 4.11 CSPC
- 4.11.1 CSPC Company Information
- 4.11.2 CSPC Business Overview
- 4.11.3 CSPC Hepatocellular Carcinoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CSPC Hepatocellular Carcinoma Drug Product Portfolio
- 4.11.5 CSPC Recent Developments
5 Global Hepatocellular Carcinoma Drug Market Scenario by Region
- 5.1 Global Hepatocellular Carcinoma Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hepatocellular Carcinoma Drug Sales by Region: 2021-2032
- 5.2.1 Global Hepatocellular Carcinoma Drug Sales by Region: 2021-2026
- 5.2.2 Global Hepatocellular Carcinoma Drug Sales by Region: 2027-2032
- 5.3 Global Hepatocellular Carcinoma Drug Revenue by Region: 2021-2032
- 5.3.1 Global Hepatocellular Carcinoma Drug Revenue by Region: 2021-2026
- 5.3.2 Global Hepatocellular Carcinoma Drug Revenue by Region: 2027-2032
- 5.4 North America Hepatocellular Carcinoma Drug Market Facts & Figures by Country
- 5.4.1 North America Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
- 5.4.3 North America Hepatocellular Carcinoma Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hepatocellular Carcinoma Drug Market Facts & Figures by Country
- 5.5.1 Europe Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
- 5.5.3 Europe Hepatocellular Carcinoma Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hepatocellular Carcinoma Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hepatocellular Carcinoma Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hepatocellular Carcinoma Drug Market Facts & Figures by Country
- 5.7.1 South America Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
- 5.7.3 South America Hepatocellular Carcinoma Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Hepatocellular Carcinoma Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hepatocellular Carcinoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hepatocellular Carcinoma Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hepatocellular Carcinoma Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hepatocellular Carcinoma Drug Sales by Type (2021-2032)
- 6.1.1 Global Hepatocellular Carcinoma Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Hepatocellular Carcinoma Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Hepatocellular Carcinoma Drug Revenue by Type (2021-2032)
- 6.2.1 Global Hepatocellular Carcinoma Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hepatocellular Carcinoma Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Hepatocellular Carcinoma Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hepatocellular Carcinoma Drug Sales by Application (2021-2032)
- 7.1.1 Global Hepatocellular Carcinoma Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Hepatocellular Carcinoma Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Hepatocellular Carcinoma Drug Revenue by Application (2021-2032)
- 7.2.1 Global Hepatocellular Carcinoma Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hepatocellular Carcinoma Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Hepatocellular Carcinoma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hepatocellular Carcinoma Drug Value Chain Analysis
- 8.1.1 Hepatocellular Carcinoma Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hepatocellular Carcinoma Drug Production Mode & Process
- 8.2 Hepatocellular Carcinoma Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hepatocellular Carcinoma Drug Distributors
- 8.2.3 Hepatocellular Carcinoma Drug Customers
9 Global Hepatocellular Carcinoma Drug Analyzing Market Dynamics
- 9.1 Hepatocellular Carcinoma Drug Industry Trends
- 9.2 Hepatocellular Carcinoma Drug Industry Drivers
- 9.3 Hepatocellular Carcinoma Drug Industry Opportunities and Challenges
- 9.4 Hepatocellular Carcinoma Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst